Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Receivables (2019 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Receivables for 7 consecutive years, with $46.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Receivables changed N/A year-over-year to $46.4 million, compared with a TTM value of $46.4 million through Mar 2025, changed N/A, and an annual FY2024 reading of $35.7 million, changed N/A over the prior year.
  • Receivables was $46.4 million for Q1 2025 at Bicycle Therapeutics, up from $35.7 million in the prior quarter.
  • Across five years, Receivables topped out at $50.0 million in Q1 2023 and bottomed at $233000.0 in Q2 2024.
  • Average Receivables over 5 years is $22.0 million, with a median of $13.5 million recorded in 2021.
  • The sharpest move saw Receivables skyrocketed 350.9% in 2023, then crashed 99.48% in 2024.
  • Year by year, Receivables stood at $11.9 million in 2021, then crashed by 82.83% to $2.0 million in 2022, then skyrocketed by 2104.89% to $45.1 million in 2023, then fell by 20.93% to $35.7 million in 2024, then surged by 30.07% to $46.4 million in 2025.
  • Business Quant data shows Receivables for BCYC at $46.4 million in Q1 2025, $35.7 million in Q4 2024, and $233000.0 in Q2 2024.